Adult Surviving Sepis Campaign Guidelines (Hour-1 Bundle)
Children's Surviving Sepsis Campaign Guidelines
Adult ICU Liberation Guidelines and Bundle (A-F)
Management of Adults with COVID-19
New User? Sign Up Free
SCCM is updating its SCCM Connect Community. Access to SCCM Connect may be limited until April 23.
SCCM has announced the cancelation of the 2022 Critical Care Congress in-person event and the postponement of the virtual event to April 18-21, 2022. Please visit sccm.org/congress2022 for important details.
Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on January 13, 2021.
Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on September 9, 2020.
From Critical Care Medicine. In this Editorial, the wonder if the use of convalescent plasma needs to be further whittled to an even smaller subset of patients and ultimately whether there is even a practical role for this therapy in the treatment of COVID-19 particularly in hospitalized patients.
From Critical Care Medicine. This is an online Letter to the Editor in response to the article by Fernandez et al. “Plasma Exchange: An Effective Rescue Therapy in Critically Ill Patients With Coronavirus Disease 2019 Infection.”
From Critical Care Explorations. The data in this study provide further evidence for plasma exchange as a novel therapeutic strategy in a subset of critically ill coronavirus disease 2019 patients by potentially reversing the complex coronavirus disease 2019 immunopathology.
From Critical Care Medicine. In this study, the authors found that administration of convalescent plasma to hospitalized patients with coronavirus disease 2019 infection increased antibodies to severe acute respiratory syndrome coronavirus disease 2 but was not associated with improved outcome.